What Is Neuroendocrine Cancer?
Understanding the biology of neuroendocrine neoplasms: comparing NETs and NECs, and why rarity complicates diagnosis.
To understand neuroendocrine cancer, we first have to understand the extraordinary cells from which it arises. Neuroendocrine cells are specialized cells found throughout the body, including the lungs, gastrointestinal tract, pancreas, and reproductive organs. They act as a vital bridge between our nervous system and endocrine (hormonal) system. When signaled by nerve impulses, neuroendocrine cells release hormones into the bloodstream to regulate essential bodily functions—such as digestion, metabolism, blood flow, and respiratory rate.
When these cells mutate and divide abnormally, they form neuroendocrine neoplasms (NENs). However, neuroendocrine cancer is not a single uniform disease; it exists along a broad and complex spectrum. Medical experts divide these neoplasms into two major categories: Neuroendocrine Tumors (NETs) and Neuroendocrine Carcinomas (NECs).
Neuroendocrine Tumors (NETs) are typically well-differentiated. Under a microscope, the tumor cells still closely resemble healthy neuroendocrine cells. While they can still metastasize and cause severe complications, NETs are often slow-growing (low- or intermediate-grade) and may develop silently over several years before producing detectable symptoms.
Neuroendocrine Carcinomas (NECs), by contrast, are poorly differentiated, high-grade malignancies. The cells divide rapidly, look disorganized and atypical, and grow aggressively. High-grade NEC behaves very differently from lower-grade NETs. It requires urgent, intensive clinical intervention and often demands systemic chemotherapy protocols similar to small cell lung cancer, regardless of where in the body the primary tumor originated.
Because neuroendocrine cancers account for only about 2% of all cancers diagnosed annually in the United States, they are classified as rare diseases. Many physicians encounter only a handful of cases in their entire careers. This rarity often leads to delayed identification or misdiagnosis, giving aggressive forms like high-grade NEC valuable time to spread.
Understanding this biological distinction between indolent NETs and aggressive NECs is vital. When Ana was diagnosed with high-grade neuroendocrine carcinoma, we learned firsthand how crucial specialized pathological evaluation is. Over the coming days, we will delve into the challenges of detecting these tumors early and why tailored research remains our best hope for effective treatments.
Ana Carolina Medina Castillo
September 5, 1992 – 2026 • Monterrey, MX & Arlington, TX
Registered Nurse (BSN, UT Arlington), devoted mother of Eliana, Elias, and Elaina, and beloved wife of Josue Negron. Her courage and grace continue to guide this platform to ensure no family faces neuroendocrine carcinoma alone.